Pharma access to low-income countries 'mixed bag' per STAT analysis

A STAT analysis finds that large pharmaceutical companies have made uneven progress in improving drug access in low- and middle-income countries, with some firms advancing while others lag. The report highlights persistent gaps in affordability and availability, though specific company-level details are not provided. This matters as it informs policy and investor scrutiny of pharma's global health commitments.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works